How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?

Author: Lindsay Colin R   Roxburgh Patricia   Graham Janet  

Publisher: Future Medicine

ISSN: 1479-6694

Source: Future Oncology, Vol.9, Iss.6, 2013-06, pp. : 825-829

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

A number of Phase II/III clinical trials have now been reported assessing the role of cetuximab use in combination with chemotherapy for the first-line treatment of metastatic colorectal cancer. Here we review the current position of cetuximab in this context from two important perspectives. First, we address whether clinicians should prioritize its use with oxaliplatin- or irinotecan-based chemotherapy doublets. Second, we review the trial evidence for the use of cetuximab in patients suffering from colorectal cancer with wild-type and mutant Ras.

Related content